Key result
Evaluation of 13 commercial FMD vaccine batches using a novel East Africa reference antigen panel revealed significant inconsistencies in cross-neutralisation responses, with only one batch meeting expected immunogenicity thresholds without a booster.
Why the study?
There is no systematic approach to demonstrate the regional relevance of inactivated foot-and-mouth disease vaccines against circulating serotypes and strains in endemic countries.
Does the East Africa reference antigen panel effectively evaluate the regional relevance and potency of commercial FMD vaccines in cattle?
Does the East Africa reference antigen panel effectively evaluate the regional relevance and potency of commercial FMD vaccines in cattle?
A newly established East Africa reference antigen panel reveals significant inconsistencies and gaps in cross-neutralization responses of commercially available FMD vaccines, highlighting the need for independent vaccine quality control.
Provides tool for regional FMD vaccine testing; leaves open adoption to rebuild trust and investment in endemic programs.
Despite widespread use of inactivated vaccines to control foot-and-mouth disease (FMD), there is no systematic approach to demonstrate the regional relevance of these products against the specific serotypes and strains that circulate in endemic countries in Africa and Asia. Failure to adopt independent testing of FMD vaccines has contributed to poor trust in their quality and a lack of investment in vaccination programmes. Therefore, a reference antigen panel representing four serotypes, tailored for East Africa, has been established and used to measure FMDV-specific antibody responses in cattle after administration of FMD vaccines commercially available in the region. This revealed inconsistencies and gaps in cross-neutralisation responses that are evident for some vaccines even after giving booster doses. It is concluded that the East Africa reference antigen panel can be used to evaluate FMD vaccine potency and drive up vaccine quality. Further panels could be developed and deployed for other endemic regions.
No takes yet. Share an insight, caveat, or question.
Paton et al. (2025) studied Foot-and-mouth disease (n=97). Commercial multivalent FMD vaccines vs. Unvaccinated controls or baseline was evaluated on Neutralising antibody responses (VNT titre ≥ 1 in 32 against ≥3 of 4 strains per serotype in ≥60% of cattle). Evaluation of 13 commercial FMD vaccine batches using a novel East Africa reference antigen panel revealed significant inconsistencies in cross-neutralisation responses, with only one batch meeting expected immunogenicity thresholds without a booster.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: